Zolunicant（Cat No.:I043355）is an investigational antimicrobial agent belonging to the novel class of bacterial topoisomerase inhibitors (NBTIs). It targets bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. By inhibiting these enzymes, Zolunicant disrupts bacterial DNA processes, leading to cell death. It exhibits broad-spectrum activity against Gram-positive and some Gram-negative pathogens, including drug-resistant strains such as MRSA. Zolunicant is being explored as a promising candidate for treating serious bacterial infections and overcoming antibiotic resistance, offering a potential new option in the fight against multidrug-resistant bacteria.